Molecular determinants of mesenchymal cell activation in fibroproliferative diseases
- PMID: 31563998
- PMCID: PMC6858579
- DOI: 10.1007/s00018-019-03212-3
Molecular determinants of mesenchymal cell activation in fibroproliferative diseases
Abstract
Uncontrolled scarring, or fibrosis, can interfere with the normal function of virtually all tissues of the body, ultimately leading to organ failure and death. Fibrotic diseases represent a major cause of death in industrialized countries. Unfortunately, no curative treatments for these conditions are yet available, highlighting the critical need for a better fundamental understanding of molecular mechanisms that may be therapeutically tractable. The ultimate indispensable effector cells responsible for deposition of extracellular matrix proteins that comprise scars are mesenchymal cells, namely fibroblasts and myofibroblasts. In this review, we focus on the biology of these cells and the molecular mechanisms that regulate their pertinent functions. We discuss key pro-fibrotic mediators, signaling pathways, and transcription factors that dictate their activation and persistence. Because of their possible clinical and therapeutic relevance, we also consider potential brakes on mesenchymal cell activation and cellular processes that may facilitate myofibroblast clearance from fibrotic tissue-topics that have in general been understudied.
Keywords: Apoptosis; De-differentiation; Differentiation proliferation; Fibroblast; Fibroproliferative diseases; Myofibroblast; Signaling pathways.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11105531/bin/18_2019_3212_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11105531/bin/18_2019_3212_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/11105531/bin/18_2019_3212_Fig3_HTML.gif)
Similar articles
-
Fibroblast growth factor-2, but not the adipose tissue-derived stromal cells secretome, inhibits TGF-β1-induced differentiation of human cardiac fibroblasts into myofibroblasts.Sci Rep. 2018 Nov 9;8(1):16633. doi: 10.1038/s41598-018-34747-3. Sci Rep. 2018. PMID: 30413733 Free PMC article.
-
Featured Article: TGF-β1 dominates extracellular matrix rigidity for inducing differentiation of human cardiac fibroblasts to myofibroblasts.Exp Biol Med (Maywood). 2018 Apr;243(7):601-612. doi: 10.1177/1535370218761628. Epub 2018 Mar 4. Exp Biol Med (Maywood). 2018. PMID: 29504479 Free PMC article.
-
The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype.BMC Biol. 2016 Mar 17;14:21. doi: 10.1186/s12915-016-0243-8. BMC Biol. 2016. PMID: 26988708 Free PMC article.
-
Understanding the origin, activation and regulation of matrix-producing myofibroblasts for treatment of fibrotic disease.J Pathol. 2013 Nov;231(3):273-89. doi: 10.1002/path.4253. J Pathol. 2013. PMID: 24006178 Review.
-
TGF-β-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases.Int J Mol Sci. 2017 Oct 17;18(10):2157. doi: 10.3390/ijms18102157. Int J Mol Sci. 2017. PMID: 29039786 Free PMC article. Review.
Cited by
-
MAPK phosphatase 1 inhibition of p38α within lung myofibroblasts is essential for spontaneous fibrosis resolution.J Clin Invest. 2024 Mar 21;134(10):e172826. doi: 10.1172/JCI172826. J Clin Invest. 2024. PMID: 38512415 Free PMC article.
-
SRC and TKS5 mediated podosome formation in fibroblasts promotes extracellular matrix invasion and pulmonary fibrosis.Nat Commun. 2023 Sep 21;14(1):5882. doi: 10.1038/s41467-023-41614-x. Nat Commun. 2023. PMID: 37735172 Free PMC article.
-
Comprehensive Ontology of Fibroproliferative Diseases: Protocol for a Semantic Technology Study.JMIR Res Protoc. 2023 Aug 11;12:e48645. doi: 10.2196/48645. JMIR Res Protoc. 2023. PMID: 37566458 Free PMC article.
-
Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype.Sci Rep. 2023 Jul 26;13(1):12137. doi: 10.1038/s41598-023-39369-y. Sci Rep. 2023. PMID: 37495732 Free PMC article.
-
Elucidating shared biomarkers and pathways in kidney stones and diabetes: insights into novel therapeutic targets and the role of resveratrol.J Transl Med. 2023 Jul 21;21(1):491. doi: 10.1186/s12967-023-04356-4. J Transl Med. 2023. PMID: 37480086 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources